QUANTRO Therapeutics Secures 12-Month AI Drug Discovery Grant

By Olivia Hart

QUANTRO Therapeutics said it secured a 12-month, non-dilutive research grant from the Austrian Research Promotion Agency (FFG) to expand its AI-powered medicinal-chemistry platform, ASCEND; the announcement did not disclose the grant amount. QUANTRO is a Vienna-based biotechnology company developing medicines that target transcription factors. QUANTRO says the financing will integrate artificial intelligence, molecular modeling and its proprietary transcriptomic data to improve drug discovery and optimization.

What does the 12-month grant fund?

QUANTRO says the grant will establish AI-driven discovery capabilities on local computing infrastructure in Vienna, reducing reliance on technology providers outside Europe. The company says the award will support continued ASCEND development as it advances its therapeutic pipeline toward preclinical candidate selection.

QUANTRO’s announcement gives no grant value, computing capacity, vendor or implementation timetable. Takeaway: The award buys a defined year of platform work, but the disclosed terms do not show its scale.

Why are transcription factors the target?

QUANTRO describes transcription factors as proteins that regulate gene expression and play important roles in numerous diseases. The company says many forms of cancer and other disorders implicate them, yet conventional drug-development approaches have historically made them difficult to target. ASCEND is designed to help QUANTRO identify and develop small molecules that target these proteins.

QUANTRO estimates that about 300 of the 1,600 transcription factors encoded in the human genome, or roughly one in five, are directly associated with disease. The company believes these proteins represent a significant therapeutic opportunity, but it provides no underlying disease mapping or candidate-level data.

The estimate indicates breadth rather than a validated development target. Takeaway: QUANTRO must convert a genome-scale opportunity into a preclinical candidate that survives testing.

How does ASCEND work?

ASCEND combines QUANTRO’s time-resolved transcriptomic technology with computational chemistry and in-house machine-learning tools. The company says its transcriptomic platform measures changes in gene expression over time, capturing transcriptional activity that conventional methods measuring steady-state RNA levels may miss.

QUANTRO intends to use those datasets to improve the identification and optimization of drug candidates, including:

• Small molecule inhibitors.
• Covalent compounds.
• Molecular glue degraders.

QUANTRO says ASCEND is initially being applied to oncology, although it designed the platform to support drug discovery across multiple therapeutic areas. Potential future applications include inflammatory disorders and additional approaches involving peptides, macrocycles and other therapeutic modalities.

The announcement offers no comparative performance data or external validation for ASCEND. Takeaway: The platform’s premise is time-resolved biology, but its claimed advantage remains unquantified.

What does local infrastructure mean for QUANTRO?

QUANTRO says operating ASCEND on local infrastructure in Vienna will strengthen scientific progress and long-term competitiveness in Austria. Michael Bauer, CEO of QUANTRO Therapeutics, said:

“We are grateful for the support of the FFG, which represents an important independent endorsement of QUANTRO’s strategy.

“This non-dilutive funding enables us to build ASCEND into a fully operational, AI-driven discovery platform, accelerating our pipeline.

“QUANTRO has a unique and proprietary capability to produce highly precise, time-resolved functional transcriptomic data, overcoming the limitations of historical methods and taking corresponding AI/ML applications to new levels.

“Developing and operating ASCEND on local infrastructure here in Vienna strengthens technological progress made in Austria, supports our long-term competitiveness, and reinforces the country’s excellent track record in scientific and technological innovation.

“With QUANTRO, we are combining technology leadership in transcriptomics with innovation in computational drug discovery.”

Bauer calls FFG support an independent endorsement, but QUANTRO’s announcement includes no FFG statement and gives no comparative accuracy data, cost analysis or implementation schedule. Local control may reduce external dependencies, but QUANTRO has not quantified the expected gains. Takeaway: The infrastructure rationale is strategic, while its measurable value remains unproven in the disclosed terms.

Who is backing the company, and what comes next?

QUANTRO was founded in 2019 as a spinout from the Institute of Molecular Biotechnology and the Research Institute of Molecular Pathology in Vienna. Boehringer Ingelheim Venture Fund and Evotec have backed the company, providing €11 million through milestone-based financing tranches in 2020 and 2023.

QUANTRO also entered a strategic collaboration with Boehringer Ingelheim Oncology involving selected cancer-related targets. The non-dilutive grant adds research funding without disclosing a new equity round or an updated total for previously raised capital. Pascal Benderitter, Head of Medicinal Chemistry at QUANTRO Therapeutics, said:

“This grant marks an important step in QUANTRO’s next phase of growth, enabling us to leverage our unique proprietary transcriptomics data and state-of-the-art technologies to discover drugs targeting transcription factors.

“Combined with our time-resolved transcriptomics technology, ASCEND will accelerate the advancement of our therapeutic pipeline towards the selection of preclinical candidates for early clinical development.”

QUANTRO did not disclose which disease programs or modalities will reach preclinical selection first, the grant value or a candidate-selection date. Takeaway: The next concrete checkpoint is preclinical candidate selection; until then, ASCEND remains a development-stage platform proposition.